From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Loading…
MRNA · NASDAQ · Biotechnology
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Institutions reporting a stake, Q2 2026
777
+54 vs Q1 2026
Share of stock reported
79.9%
319M of 399M shares outstanding
Change vs Q1 2026
+8.02M shares
130 new positions, 82 positions closed
Reported in 13F filings, which cover managers over $100M and include double counting. A 13F shows holdings on the last day of the quarter, not when shares were bought or sold. Change counts the 759 managers that reported both quarters.
Source: SEC Form 13F data sets, every filer, common stock only (options and bonds left out); 39 managers also reported puts and 38 managers calls. Amendments are applied; lines whose value was filed in thousands are scaled, and lines whose shares and value disagree are left out.